Literature DB >> 2321994

The effect of topical tretinoin on dysplastic nevi. A preliminary trial.

L Edwards1, P Jaffe.   

Abstract

Twenty-one patients were enrolled in a randomized, double-blind study that examined the effects of topical 0.05% tretinoin (all-trans-retinoic acid; vitamin A acid; Retin-A) solution on dysplastic nevi. Following histologic confirmation of the diagnosis of dysplastic nevus in three representative lesions, patients applied either tretinoin or a placebo containing 50% alcohol to selected dysplastic nevi once a day under tape occlusion, or twice a day unoccluded, for 4 months. Immediate posttreatment comparative photographs showed marked fading or elimination of some dysplastic nevi clinically, and histologic examination of excisional biopsy specimens showed disappearance or reversion to benign nevi in many of the treated lesions. There were no clinical or histologic changes in those dysplastic nevi treated with placebo. This study shows a definite biological effect of topical tretinoin on some dysplastic nevi.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2321994

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  5 in total

Review 1.  The detection and management of dysplastic nevi and early melanoma.

Authors:  J K Rivers
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 2.  Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Authors:  Joanne M Jeter; Tawnya L Bowles; Clara Curiel-Lewandrowski; Susan M Swetter; Fabian V Filipp; Zalfa A Abdel-Malek; Larisa J Geskin; Jerry D Brewer; Jack L Arbiser; Jeffrey E Gershenwald; Emily Y Chu; John M Kirkwood; Neil F Box; Pauline Funchain; David E Fisher; Kari L Kendra; Ashfaq A Marghoob; Suephy C Chen; Michael E Ming; Mark R Albertini; John T Vetto; Kim A Margolin; Sherry L Pagoto; Jennifer L Hay; Douglas Grossman; Darrel L Ellis; Mohammed Kashani-Sabet; Aaron R Mangold; Svetomir N Markovic; Frank L Meyskens; Kelly C Nelson; Jennifer G Powers; June K Robinson; Debjani Sahni; Aleksandar Sekulic; Vernon K Sondak; Maria L Wei; Jonathan S Zager; Robert P Dellavalle; John A Thompson; Martin A Weinstock; Sancy A Leachman; Pamela B Cassidy
Journal:  Cancer       Date:  2018-10-03       Impact factor: 6.860

3.  Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.

Authors:  Clara Curiel-Lewandrowski; Susan M Swetter; Janine G Einspahr; Chiu-Hsieh Hsu; Ray Nagle; Paul Sagerman; Joseph Tangrea; Howard Parnes; David S Alberts; Hsiao-Hui Chow
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

4.  Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma.

Authors:  K Dhingra; N Papadopoulos; S Lippman; R Lotan; S S Legha
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

Review 5.  Retinoids: present role and future potential.

Authors:  T R Evans; S B Kaye
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.